Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating
Bloom Burton Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $9
A Quick Look at Today's Ratings for AbCellera Biologics(ABCL.US), With a Forecast Between $7 to $12
AbCellera Biologics Analyst Ratings
Benchmark Co. Maintains AbCellera Biologics(ABCL.US) With Hold Rating
TD Cowen Initiates AbCellera Biologics(ABCL.US) With Buy Rating
TD Cowen Remains a Buy on AbCellera Biologics (ABCL)
KeyBanc Maintains AbCellera Biologics(ABCL.US) With Buy Rating
Benchmark Co. Downgrades AbCellera Biologics(ABCL.US) to Hold Rating
Strong Liquidity and Strategic Alliances Underpin Buy Rating for AbCellera Biologics
Understanding the Buy Rating: A Synopsis of AbCellera Biologics' Investment Potential
TD Cowen Maintains AbCellera Biologics(ABCL.US) With Buy Rating
TD Cowen Remains a Buy on AbCellera Biologics (ABCL)
KeyBanc Adjusts Price Target on AbCellera Biologics to $5 From $7, Maintains Overweight Rating
AbCellera Biologics Analyst Ratings
Keybanc Maintains Overweight on AbCellera Biologics, Lowers Price Target to $5
KeyBanc Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
Keybanc: Maintaining the ABCellera Biologics (ABCL.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $8.00 to $7.00.
AbCellera Biologics Analyst Ratings